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Summary 
Dysregulation of calcium signals due to defects of the skeletal muscle sarcoplasmic 
reticulum calcium release channel (ryanodine receptor; RyR1) is causative of several congenital 
muscle disorders including malignant hyperthermia (MH; MIM #145600), Central Core Disease 
(CCD; MIM #11700), specific forms of Multi-minicore Disease (MmD; MIM # 255320) and 
Centronuclear myopathy (CNM).  Experimental data have shown that RYR1 mutations result 
mainly in four types of channel defects: one class of RYR1 mutations (MH) cause the channels to 
become hypersensitive to activation by electrical and pharmacological stimuli. The second class 
of RYR1 mutations (CCD) result in leaky channels leading to depletion of Ca2+ from SR stores. A 
third class of RYR1 mutations linked to CCD causes excitation-contraction uncoupling, whereby 
activation of the voltage sensor Cav1.1 is unable to release calcium from the SR. The fourth class 
of mutations are unveiled by wild type allele silencing, and cause a decrease of mutant RyR1 
channels expression on SR membranes. In this review, we discuss the classes of RYR1 mutations 
which have been associated with CCD, MmD and  related neuromuscular phenotypes. 
 
Introduction 
Although 5 decades of research into the mechanisms involved in cytosolic Ca2+ 
regulation have advanced our understanding of fundamental cellular processes ranging from 
muscle contraction to gene expression [1], the precise impact of altered Ca2+ signalling on 
human disease has remained elusive for a long time. The discovery of genes encoding key 
proteins involved in Ca2+ homeostasis was fundamental in bridging the gap between 
understanding the role of Ca2+ in basic physiological processes and the pathophysiology of 
human diseases. The identification of the Ca2+ release channel protein (ryanodine receptor, 
RyR1) of striated muscle [2] and the identification of mutations in its gene, RYR1 [3], allowed 
for the first time a direct correlation between altered Ca2+ homeostasis and muscle disease 
(Fig.1), in particular Malignant Hyperthermia (MH) [4-6], Central Core Disease (CDD) [7], 
specific forms of Multi-minicore disease (MmD) [8-10] and centronuclear myopathy (CNM) 
[11] (Tab.1). The overall population frequency of RYR1 mutations (about 1:50000) is likely to 
have been underestimated as suggested by the finding of compound heterozygosity or 
homozygosity for RYR1 mutations in some patients within extensively analyzed MH and CCD 
pedigrees and other rare disorders including MmD [8-10], exercise-induced rhabdomyolysis 
[12], and some forms of exercise-induced hyperthermia [13]. 
 
The Ryanodine Receptor calcium channels 
Ryanodine receptors are members of a family of intracellular Ca2+ release channel proteins 
present on ER/SR membranes [14]. Type 1 RyR is encoded by a gene on human chromosome 
19q13.1 [15], and is mainly expressed in skeletal muscle and to a lower level in Purkinje cells 
[16], human B-lymphocytes [17,18], and dendritic cells [19-22]; this implies that mutations in the 
RYR1 might affect not only excitable cells but also the immune system and other tissues. The 
functional calcium release channel is made up of four protomers forming a large macromolecular 
complex of approx. 2,500,000 Da. The complex contains a large hydrophilic domain and a 
relatively small hydrophobic COOH-terminal domain containing several transmembrane (TM) 
segments [23-25]. The RYR1 displays three mutation hot spot regions, of which two are localised 
in the large hydrophilic region and the third in the COOH-terminal TM domain [5,26] (Fig. 2). 
Most of the CCD linked mutations are localised within and around a short hydrophobic segment 
between the last two transmembrane segments, a region which is thought to form the pore helix 
and the selectivity filter of the RyR channels [25,27,28], whereas MmD (and CNM) linked RYR1-
mutations are distributed along the entire coding sequence. 
Central Core Disease  
CCD is usually inherited as an autosomal dominant (AD) trait [7] but recessive 
inheritance has been recently described in few families [29-32]. The clinical phenotype of 
dominantly inherited CCD is variable but usually mild and non-progressive; however, more 
severe forms including the foetal akinesia syndrome have also been reported [33] associated with 
recessive or de novo dominant mutations. Type I fibre predominance and hypotrophy are 
common; cores are typically centrally located, cover a considerable length of the fibre and lack 
mitochondria and oxidative enzymes. Electron microscopy reveals variable degrees of 
disintegration of the contractile apparatus within the core region, from Z line streaming to total 
loss of myofibrillar structure. In most cases, patients with dominant CCD carry mutations in the 
RYR1 gene; with few exceptions these are clustered in the hydrophobic COOH-terminal pore-
forming region of the molecule (domain 3) [5,26,30].  
Functional effects of RYR1 mutations linked to CCD.  
Two hypotheses have been suggested to explain the functional effect of CCD-linked RYR1 
mutations: the first one suggests that these mutations lead to leaky channels, depletion of SR 
Ca2+ stores and consequently muscle weakness [26, 34-37].  This “leaky channel” hypothesis has 
been challenged by data obtained using myotubes from the RyR1 knock out animals 
reconstituted with recombinant RyR1 cDNA carrying mutations in the COOH-terminal domain 
which have suggested an alternative “E-C uncoupling” hypothesis [34,38]. According to the 
latter hypothesis, CCD mutations in the hot spot domain #3 lead to functional uncoupling of 
sarcolemma depolarisation from release of Ca2+ from the SR Ca2+ stores [34]. The kernel of the 
two hypothesis concerns the extent of the Ca2+ load in the lumen of the SR from CCD muscles 
[26]: the uncompensated Ca2+ leak hypothesis predicts a decrease of the SR Ca2+ load, while the 
E-C uncoupling hypothesis predicts that the muscle weakness does not result from major 
changes in the SR Ca2+ levels, but rather is due to a defect in excitation contraction coupling 
(ECC), the molecular mechanism underlying the transmission of the signal from sarcolemma 
depolarisation to the RyR.  To discriminate between these two pathogenetic hypotheses it is 
crucial to define (i) SR Ca2+ content in muscle cells from CCD patients carrying mutation in the 
COOH-terminal domain, and (ii) clearly establish the role of SR Ca2+ load in the regulation of 
Ca2+ release in mammalian fibres [39]. If the Ca2+ leak hypothesis is correct, the prevalent 
involvement of type I fibres suggests that the extent of Ca2+ leak via mutated RyR is higher in 
slow fibres compared to fast fibres, and likely reflects larger SR Ca2+ load of slow twitch 
muscles [40].  A knock-in CCD mouse model carrying the heterozygous RyR1 I4895T mutation 
does not reconstitute the severe CCD skeletal muscle phenotype of humans harbouring 
homologous heterozygous RYR1 mutations [41]. It appears that the CCD knock-in mice 
phenotype is somehow different from its human counterpart since, in addition to dysfunctional 
RyR1, homozygous mice display perinatal death, embryonic developmental defect of the skin, 
bones and cardiovascular system. 
Multi-minicore Disease 
 MmD disease is an autosomal recessive early onset congenital myopathy [42]. Muscle 
biopsies from MmD patients show multiple small areas (cores) of sarcomeric disorganization 
lacking oxidative enzymes and mitochondria, which typically do not run the length of the muscle 
fibre. MmD is clinically highly variable (Tab. 1) and genetically heterogeneous having been 
linked to recessive mutations both in the selenoprotein 1 (SEPN1)(Tab.2) gene and the skeletal 
muscle RYR1 gene [43-46]. Although genotype-phenotype correlations have not been fully 
established, it appears that extra-ocular muscle involvement is exclusive to the RYR1-related 
form of MmD, whilst severe scoliosis and respiratory impairment requiring ventilatory support 
are more prevalent in SEPN1-related “classical” MmD [44,45,47]. 
Selenoprotein N (SEPN1) mutations  
The selenoproteins are a family of proteins characterised by the presence of the 21st amino acid 
selenocysteine in their primary structure. Selenocysteine represents the main biological form of 
selenium [48]. The selenoprotein SEPN1, which is encoded by a gene (SEPN1; MIM#606210) 
on human chromosome 1p36 (RSMD1 locus), is a 70 kDa integral membrane glycoprotein 
localized in the endoplasmic reticulum of many tissues, including pancreas, kidney, heart, liver, 
lung, brain and skeletal muscle [49]. Approximately 20 mutations have been identified within the 
coding sequence of the SEPN1 gene (Tab. 2), and half of the mutations identified in patients with 
the classical form of MmD give rise to a truncated SEPN1 protein. It has recently been shown 
that selective down regulation of SEPN-1 in zebra fish muscles causes alterations (i) in the 
organization and attachment of the myofibrils and (ii) in the formation of myoseptum, a structure 
homologous to the human myotendineuos junction [50]. The decrease of SEPN1 synthesis might 
be associated with an intracellular accumulation of selenite, a precursor of the selenocysteine 
synthetase [51]; the intracellular accumulation of selenite might in turn alter the redox 
modulation of the RyR1 [52,53]. 
RYR1 mutations  
A consistent number of MmD patients, particularly those with associated extra-ocular 
involvement, harbour recessive mutations in RYR1 [45,54]. The first functional study of MmD-
related RYR1 mutations demonstrated that the p.P3527S and p.V4849I substitutions are 
associated with a slightly elevated resting Ca2+ concentration, but not depleted intracellular 
stores [55]. Interestingly, cells carrying the homozygous P3527S RYR1 mutation were found to 
release significantly less Ca2+after pharmacological activation. Similarly, in another study it was 
shown that RyR macromolecular complexes carrying the p.S71Y+p.N2283H compound 
heterozygous mutations did not exhibit reduced Ca2+ release after pharmacological stimulation 
[31]. On the other hand, one of the mutations (p-N2283H) actually increased the sensitivity of 
the RyR1 activation by KCl and caffeine and is probably also linked to the MHS phenotype. In 
some MmD patients, particularly those with ophthalmoplegia, the clinical phenotype may be at 
least partly explained by a decrease of the RyR1 channel density in the junctional sarcoplasmic 
reticulum membrane, as demonstrated by Western blot analysis with anti-RyR Ab of muscles 
obtained from patients carrying the p.R109W+p.M485V as well as other recessive mutations 
[31,32,56], and the homozygous 14646+2.99 kb intronic splicing variant [47]. In some of these 
patients with recessive core myopathies, heterozygosity for the RYR1 mutation at the genomic 
level but apparent monoallelic expression in muscle (mimicking homozygosity), suggested that 
the RyR1 decrease resulted from muscle specific RYR1 gene silencing [56]. In fact, in these 
patients, the only allele transcribed in skeletal muscle carried the mutation and was paternally 
inherited [56]. One of the families where wild type allele silencing occurred carried the 
p.R109W+p.M485V substitutions. The p.M485V substitution did not affect the function of the 
RyR in a discernable way [31], whereas the p.R109W homozygous mutation was associated with 
(i) very low levels of RyR1 in the muscle from the affected patient, and (ii) a significant decrease 
of ryanodine binding and inability to transport calcium by the recombinant mutant channel 
expressed in HEK293 cells. 
Centronuclear myopathy 
Centronuclear myopathy (CNM) is a rare, genetically heterogeneous congenital 
myopathy characterized by numerous centrally located nuclei; additional but inconsistent 
histopathological features comprise a central zone either devoid of oxidative enzyme activity or 
with oxidative enzyme accumulation, radial strands surrounding the central area, type 1 fibre 
predominance and hypotrophy. CNM exists in X-linked, autosomal-dominant and recessive 
forms and mutations in several genes whose products play a role in membrane trafficking have 
been identified (Tab.3). The most severe and often fatal X-linked form (“myotubular myopathy”) 
is associated with mutations in the myotubularin MTM1 gene [57,58], whereas autosomal 
dominant and autosomal recessive forms have been attributed to mutations in a number of genes 
including DNM2 and amphiphysin (BIN1) (Tab. 3) [59-61]. In a recent report, a dominant de 
novo RYR1 mutation was identified in a patient with histopathologic and clinical features of 
CNM and a pattern of selective muscle involvement on MR imaging suggestive of RYR1 
involvement [11]. Nevertheless, the overall frequency of RYR1 mutations in this phenotype is 
currently unknown. Mutation analysis identified the p.S4112L RYR1 substitution  (c12335C>T) 
which lies within MH/CCD domain 3 in a region lying on the myoplasmic loop adjacent to the 
first putative transmembrane domain.  
Imaging of Ca2+ fluxes in primary cultured myotubes from the CNM patient carrying the 
p.S4112L RYR1 mutation in the COOH domain revealed an increased sensitivity to 
depolarization-induced Ca2+ release [11], suggesting that this mutation might affect long range 
interactions between the transmembrane COOH terminal domain and the region involved in the 
RyR1/Cav.1.1 intermolecular signalling [62]. Alterations of such long range interactions would 
result in a more sensitive calcium release induced by the activation of the Cav1.1 voltage sensor, 
but it is unclear how these alterations would determine the clinical phenotype of CNM.  
These data suggest that in the future, RYR1 screening ought to be considered in CNM 
patients with suggestive clinical and radiological features, in whom other genetic defects have 
been excluded. 
 
Conclusions. 
During the last few years the general understanding of congenital muscle disorders has 
greatly improved thanks to the identification of causative mutations in the RYR1 gene. However, 
the development of therapeutic treatments for affected patients has been hampered by the poor 
understanding of the molecular pathological mechanisms of the RyR1 defects. Understanding the 
mechanism(s) responsible for RYR1 allele silencing, discriminating between Ca2+ leak and EC 
uncoupling are important not only to improve our basic knowledge of the “ryanodinopathies”, 
but also to develop effective therapeutic strategies aimed at treating the muscle weakness in 
patients with these conditions.  
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Figure Legends 
Figure 1: Classification of RyR1 channelopathies based on the functional effect of 
mutations. 
 
 
 
 
 
 
 
 
 
Figure 2: Cartoon depicting the ryanodine receptor tetramer inserted into a lipid bilayer. 
The mutations identified in the different domains, their mode of transmission (D= 
dominant; r= recessive) as well as their association with CCD and MmD are indicated. 
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